Skip to content Skip to footer
Subscribe Now
Viewpoints_Anthony Costello
VIEWPOINTS

PharmaShots Interview: Medidata’s Anthony Costello Shares Insights on the Transformative Sensor Cloud Platform for Connected Devices and Wearable Sensors in Clinical Trials

In an interview with PharmaShots, Anthony Costello, President, Patient Cloud at Medidata share his views on the launch of Sensor Cloud which is a transformative platform for managing a sensor and digital health technology data during the clinical trials. Shots: The company launches Sensor Cloud for managing sensor and digital health technology data during the clinical trial.…
May 25, 2021

Read more

Viewpoints_Dr. Allitia DiBernardo
VIEWPOINTS

PharmaShots Interview: Janssen’s Dr. Allitia DiBernardo Shares Insights on the Availability of Ponvory in the US

In an interview with PharmaShots, Dr. Allitia DiBernardo, Global Head of Medical Affairs for Neurology at the Janssen share her views on the availability of Ponvory in the US for MS patients. Shots: Ponvory offers patients superior efficacy in reducing annualized relapses and brain lesions over established oral therapy teriflunomide (Aubagio), with a safe and generally well-tolerated profile…
May 24, 2021

Read more

Viewpoints_Dipal Doshi
VIEWPOINTS

PharmaShots Interview: Entrada’s Dipal Doshi Shares Insights on the Series B Funding Utilize to Advance DMD Program into the Clinic

In an interview with PharmaShots, Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics share his views on $116M Series B financing and what does this milestone means for the company's pipeline. Shots: The Series B financing was led by Wellington Management Company, who was joined by Redmile Group, TCG Crossover, Greenspring Associates, Point72, Qatar Investment…
May 19, 2021

Read more

Viewpoints_Andrew Spiegel
VIEWPOINTS

PharmaShots Interview: GCCA’s Andrew Spiegel Shares Insights on the Clear Your View Campaign

In an interview with PharmaShots, Andrew Spiegel, Executive Director of the Global Colon Cancer Association shares the details of the campaign and put colors on the impact of complete biomarker testing for advanced CRC patients. Shots: The Clear Your View campaign is an awareness initiative sponsored by Guardant Health to raise awareness of the importance of complete biomarker testing…
May 18, 2021

Read more

Viewpoints_Sneha Nair and Claire Crossett
VIEWPOINTS

PharmaShots Interview: Women First Digital’s Sneha Nair and Claire Crossett Share Insights on the Launch of World’s First Abortion Virtual Assistant, Ally on WhatsApp

In an interview with PharmaShots, Sneha Nair, Global Communications Officer and Claire Crossett, Assistant Director at Women First Digital share insight on the launch of the world's first-ever abortion virtual assistant, Ally, on WhatsApp in celebration of World Health Day's 2021 theme: Building a fairer, healthier world. Shots: Ally, the HowToUse chatbot, is equipped to answer all medical abortion-related…
May 17, 2021

Read more

Viewpoints_Gilles Cottier
VIEWPOINTS

PharmaShots Interview: Aceto’s Gilles Cottier Shares Insight on the Acquisition of A&C and IsleChem

In an interview with PharmaShots, Gilles Cottier, Chief Executive Officer of Aceto shared his views on the acquisitions of A&C and IsleChem to highlight the company's growth strategy. Shots: The acquisition of IsleChem has allowed the company to expand its manufacturing expertise in the US. Aceto currently has diversified access to a robust global supply chain network The acquisition…
May 11, 2021

Read more

Viewpoints_Dr. Med. Steven Hildemann
VIEWPOINTS

PharmaShots Interview: Ipsen’s Dr. Med. Steven Hildemann Shares Insight on the EC’s Approval of Cabometyx + Nivolumab for Advanced Renal Cell Carcinoma

In an interview with PharmaShots, Prof. Dr. Med. Steven Hildemann, Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs, and Patient Safety of Ipsen share his views on the approval of the combination regimen for aRCC. He also shed light on the company's near-term goals in the coming years. Shots: The EC approval is based…
May 11, 2021

Read more

Viewpoints_Thierry Abribat
VIEWPOINTS

PharmaShots Interview: Amolyt Pharma’s Thierry Abribat Shares Insight on AZP-3601 for Hypoparathyroidism

In an interview with PharmaShots, Thierry Abribat, Founder and Chief Executive Officer of Amolyt Pharma share his views on the clinical profile of AZP-3601. He also shed light on how it differs from other treatments in development for hypoparathyroidism. Shots: Amolyt Pharma presented positive data from the single ascending dose (SAD) portion of its Ph1 study evaluating AZP-3601…
May 10, 2021

Read more

Insights+ Key Biosimilars Events of April 2021
INSIGHTS+

Insights+ Key Biosimilars Events of April 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of April, Biocon and Viatris received EC's approval for…
May 6, 2021

Read more

Load more